AstraZeneca dual immunotherapy approved for US liver cancer patients
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
List view / Grid view
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
COVID-19 has accelerated the decline in late-stage industry clinical research in the UK, compared to its global peers.
Clinical trial results suggest adult HIV patients can be protected against hepatitis B with a three-dose vaccine series.
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
Shingrix can effectively vaccinate adults over 50 years old against shingles for at least 10 years, new data shows.
City of Hope has developed AOH1996, a promising cancer medicine, for people with reoccurring solid tumours.
Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.
Near-term gains from outsourcing biopharma R&D activities can be offset by slower innovation in the long run, according to a recent paper.
Yescarta approved by EC for the treatment of large B-Cell lypmphoma and high grade B-cell lymphoma.
Takeda’s novel dengue vaccine has received positive opinion from the EMA’s human medicines committee (CHMP), demonstrating the vaccine is safe for patients from four years old.
A new Phase II trial will study the drug ENT-01 for Parkinson’s Disease (PD)-associated dementia at sites in the UK and US.
Results from a clinical study by Astellas have demonstrated the effectiveness of fezolinetant as a treatment for menopause-associated VMS.
The oral medication Hydromethylthionine mesylate (HMTM) is the first anti-tau disease-modifying therapy to offer sustained cognitive improvement in Alzheimer’s.
The new methodology will assess the carbon impact of clinical trials and recommend ways to reduce it.
The FDA has approved Boostrix, the first vaccine for pregnant women in their third trimester, to stop whooping cough (Pertussis) in infants below two months.